A Randomized, Double-blind, Placebo-controlled Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of XQ-001 for Inhalation in Healthy Subjects
Latest Information Update: 17 Apr 2025
At a glance
- Drugs XQ 001 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Brilliant Inspiration Biotherapeutics
Most Recent Events
- 17 Apr 2025 New trial record